ChemGenex Pharmaceuticals Limited Investigators Report Omacetaxine Effective in Killing CML Stem Cells in Animal Model Studies

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that pre-clinical data characterizing the mechanism of action of omacetaxine mepesuccinate (formerly known as Ceflatonin®) were presented yesterday at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. Study results demonstrate that omacetaxine, down-regulating the key protein Mcl-1, had a direct anticancer effect on leukemic stem cells that was not exhibited by the tyrosine kinase inhibitor imatinib.
MORE ON THIS TOPIC